Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting

Karin Jordan, Axel F Grothey, Thomas Kegel, Christian Fibich, Christoph Schöber

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV). Patients and Methods: In an open monocentric study, an oral suspension containing 2 mg granisetron and 16 mg (4 mg for moderately emetogenic chemotherapy) dexamethasone was administered to 43 chemotherapy-naive patients before highly (n = 16) or moderately (n = 27) emetogenic chemotherapy and on the 3 subsequent days (2 for moderately emetogenic chemotherapy). Emetic episodes were recorded and quality of life was assessed prior to each cycle with a questionnaire based on EORTC QLQ-30. Results: In the group undergoing highly (moderately) emetogenic chemotherapy, complete control of acute vomiting was achieved in 60-72.7% (92.6-95.0%), and complete control of delayed vomiting in 37.5-40.0% (75.0-92.2%), of patients within the first 3 (5) cycles. The following quality-of-life parameters were significantly associated with PCNV: tiredness (RR = 1.3, p < 0.05), pain (RR = 1.5), impairment of daily life by pain (RR = 1.7), sensation of abdominal pressure and fullness (RR = 2.5), impairment of social activities (RR = 2.9). Conclusions: Once-daily oral administration of a suspension of granisetron/dexamethasone is an active prophylaxis of nausea and vomiting and compares favorably with data reported on intravenous administration. Quality-of-life parameters assessed pre-treatment could help to identify patients at high risk for nausea and vomiting so that antiemetic therapy can be tailored to individual patient risk.

Original languageEnglish (US)
Pages (from-to)88-92
Number of pages5
JournalOnkologie
Volume28
Issue number2
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Granisetron
Antiemetics
Nausea
Dexamethasone
Vomiting
Suspensions
Quality of Life
Drug Therapy
Emetics
Pain
Intravenous Administration
Oral Administration
Pressure
Therapeutics

Keywords

  • 5-HT receptor antagonist
  • Antiemetic prophylaxis
  • Chemotherapy
  • Granisetron
  • Quality of life

ASJC Scopus subject areas

  • Oncology

Cite this

Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. / Jordan, Karin; Grothey, Axel F; Kegel, Thomas; Fibich, Christian; Schöber, Christoph.

In: Onkologie, Vol. 28, No. 2, 2005, p. 88-92.

Research output: Contribution to journalArticle

Jordan, Karin ; Grothey, Axel F ; Kegel, Thomas ; Fibich, Christian ; Schöber, Christoph. / Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. In: Onkologie. 2005 ; Vol. 28, No. 2. pp. 88-92.
@article{5507a02bc9b045fcacf22430f13ab2d0,
title = "Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting",
abstract = "Objectives: To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV). Patients and Methods: In an open monocentric study, an oral suspension containing 2 mg granisetron and 16 mg (4 mg for moderately emetogenic chemotherapy) dexamethasone was administered to 43 chemotherapy-naive patients before highly (n = 16) or moderately (n = 27) emetogenic chemotherapy and on the 3 subsequent days (2 for moderately emetogenic chemotherapy). Emetic episodes were recorded and quality of life was assessed prior to each cycle with a questionnaire based on EORTC QLQ-30. Results: In the group undergoing highly (moderately) emetogenic chemotherapy, complete control of acute vomiting was achieved in 60-72.7{\%} (92.6-95.0{\%}), and complete control of delayed vomiting in 37.5-40.0{\%} (75.0-92.2{\%}), of patients within the first 3 (5) cycles. The following quality-of-life parameters were significantly associated with PCNV: tiredness (RR = 1.3, p < 0.05), pain (RR = 1.5), impairment of daily life by pain (RR = 1.7), sensation of abdominal pressure and fullness (RR = 2.5), impairment of social activities (RR = 2.9). Conclusions: Once-daily oral administration of a suspension of granisetron/dexamethasone is an active prophylaxis of nausea and vomiting and compares favorably with data reported on intravenous administration. Quality-of-life parameters assessed pre-treatment could help to identify patients at high risk for nausea and vomiting so that antiemetic therapy can be tailored to individual patient risk.",
keywords = "5-HT receptor antagonist, Antiemetic prophylaxis, Chemotherapy, Granisetron, Quality of life",
author = "Karin Jordan and Grothey, {Axel F} and Thomas Kegel and Christian Fibich and Christoph Sch{\"o}ber",
year = "2005",
doi = "10.1159/000082523",
language = "English (US)",
volume = "28",
pages = "88--92",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting

AU - Jordan, Karin

AU - Grothey, Axel F

AU - Kegel, Thomas

AU - Fibich, Christian

AU - Schöber, Christoph

PY - 2005

Y1 - 2005

N2 - Objectives: To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV). Patients and Methods: In an open monocentric study, an oral suspension containing 2 mg granisetron and 16 mg (4 mg for moderately emetogenic chemotherapy) dexamethasone was administered to 43 chemotherapy-naive patients before highly (n = 16) or moderately (n = 27) emetogenic chemotherapy and on the 3 subsequent days (2 for moderately emetogenic chemotherapy). Emetic episodes were recorded and quality of life was assessed prior to each cycle with a questionnaire based on EORTC QLQ-30. Results: In the group undergoing highly (moderately) emetogenic chemotherapy, complete control of acute vomiting was achieved in 60-72.7% (92.6-95.0%), and complete control of delayed vomiting in 37.5-40.0% (75.0-92.2%), of patients within the first 3 (5) cycles. The following quality-of-life parameters were significantly associated with PCNV: tiredness (RR = 1.3, p < 0.05), pain (RR = 1.5), impairment of daily life by pain (RR = 1.7), sensation of abdominal pressure and fullness (RR = 2.5), impairment of social activities (RR = 2.9). Conclusions: Once-daily oral administration of a suspension of granisetron/dexamethasone is an active prophylaxis of nausea and vomiting and compares favorably with data reported on intravenous administration. Quality-of-life parameters assessed pre-treatment could help to identify patients at high risk for nausea and vomiting so that antiemetic therapy can be tailored to individual patient risk.

AB - Objectives: To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV). Patients and Methods: In an open monocentric study, an oral suspension containing 2 mg granisetron and 16 mg (4 mg for moderately emetogenic chemotherapy) dexamethasone was administered to 43 chemotherapy-naive patients before highly (n = 16) or moderately (n = 27) emetogenic chemotherapy and on the 3 subsequent days (2 for moderately emetogenic chemotherapy). Emetic episodes were recorded and quality of life was assessed prior to each cycle with a questionnaire based on EORTC QLQ-30. Results: In the group undergoing highly (moderately) emetogenic chemotherapy, complete control of acute vomiting was achieved in 60-72.7% (92.6-95.0%), and complete control of delayed vomiting in 37.5-40.0% (75.0-92.2%), of patients within the first 3 (5) cycles. The following quality-of-life parameters were significantly associated with PCNV: tiredness (RR = 1.3, p < 0.05), pain (RR = 1.5), impairment of daily life by pain (RR = 1.7), sensation of abdominal pressure and fullness (RR = 2.5), impairment of social activities (RR = 2.9). Conclusions: Once-daily oral administration of a suspension of granisetron/dexamethasone is an active prophylaxis of nausea and vomiting and compares favorably with data reported on intravenous administration. Quality-of-life parameters assessed pre-treatment could help to identify patients at high risk for nausea and vomiting so that antiemetic therapy can be tailored to individual patient risk.

KW - 5-HT receptor antagonist

KW - Antiemetic prophylaxis

KW - Chemotherapy

KW - Granisetron

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=14244262890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244262890&partnerID=8YFLogxK

U2 - 10.1159/000082523

DO - 10.1159/000082523

M3 - Article

VL - 28

SP - 88

EP - 92

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 2

ER -